Nuvectis Pharma announces initiation of NXP9000 Phase 1a trial

Nuvectis Pharma announced the initiation of a Phase 1a dose escalation clinical trial of NXP900, its novel inhibitor of the SRC/YES1 kinase family. The study is designed to evaluate the safety, tolerability and pharmacokinetic properties of NXP900 in patients with advanced solid tumors. “Advancing NXP900 into its first in human clinical trial is an important milestone for Nuvectis,” said Ron Bentsur, Co-Founder, Chairman and Chief Executive Officer of Nuvectis, who added, “We believe that NXP900’s unique mechanism of action, which completely shuts down signaling via SFK, in conjunction with its high target specificity, differentiates it from other multi-kinase inhibitors that also inhibit SFK and provide it with the potential to become the first SFK inhibitor for the treatment of solid tumors.”